Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Multiple Myeloma × Anthracyclines × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 7 Leukemia, Myeloid, Acute 2 Triple Negative Breast Neoplasms 1 Thrombocythemia, Essential 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neoplasms 1 Myeloproliferative Disorders 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia 1 Cardiovascular Diseases 1 Cardiotoxicity 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

Dexamethasone 320 Bortezomib 210 Lenalidomide 170 Cyclophosphamide 156 Melphalan 144 Calcium Dobesilate 90 Peripheral Blood Stem Cell Transplantation 81 Thalidomide 70 fludarabine phosphate 69 Filgrastim 64 carfilzomib 54 pomalidomide 53 Granulocyte Colony-Stimulating Factor 51 daratumumab 49 ixazomib 48 Whole-Body Irradiation 48 Busulfan 47 Mycophenolic Acid 46 Prednisone 45 fludarabine 41 Tacrolimus 41 Cyclosporine 40 Antilymphocyte Serum 30 dexamethasone acetate 27 Etoposide 25 Radiotherapy 24 plerixafor 22 dexamethasone 21-phosphate 22 Methotrexate 22 Bendamustine Hydrochloride 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02288741 2014-11-11

DSMM-II

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 3 Completed

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡